Cancers 2020, 12 S1 of S1

Supplementary Materials: CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1- Malignant B Cells While Sparing CD19+HLA-C1+ Healthy B Cells +

Lei Tao, Muhammad Asad Farooq, Yaoxin Gao, Li Zhang, Congyi Niu, Iqra Ajmal, Ying Zhou, Cong He, Guixia Zhao, Jie Yao, Mingyao Liu and Wenzheng Jiang




Figure S1. HLA-C1 expression in primary T cells. HLA-C1 expression on surface of T cells was analyzed by flow cytometry with PE-anti-human HLA-C antibody. Data are representative of 3 different donors.




Figure S2. The expression of P-Zap70 in CD19-CAR-T or iKP-19-CAR-T cells at day 10. **A**, The expression of P-Zap70 in CD19-CAR-T or iKP-19-CAR-T cells was assayed by flow cytometry with PE-anti-human P-Zap70 antibody and data are representative of 3 different experiments. **B**, MFI of P-Zap70 was statistically analyzed. ns, not significant. Error bars represent \pm SD.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).